Sign In
Buy TWST
$91.55
+0.220 (+0.241%)
At Close: Jul 31, 2026
Twist Bioscience Announces Fiscal 2025 Third Quarter Financial Results
07:15am, Monday, 04'th Aug 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced financial results and business highlights for the third quarter
Twist Bioscience Expands In Vivo Antibody Discovery Services with Launch of Humanized Transgenic Mouse Model
08:00am, Thursday, 31'st Jul 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today
TWST vs. NTRA: Which Genomics Play Is a Better Buy?
11:53am, Friday, 25'th Jul 2025
Cathie Wood's Ark funds have been really heating up in recent months. Perhaps her most intriguing and underrated fund is the Ark Genomics Revolution ETF (ARKG), which is packed full of extraordinary b
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Thursday, 24'th Jul 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth
Twist Bioscience: Still Not There Yet
04:02pm, Tuesday, 15'th Jul 2025
Twist Bioscience continues to grow revenue at a healthy pace, posting 23% year-over-year sales growth and beating EPS expectations in its most recent quarter. The company holds $255 million in cash an
Twist Bioscience to Report Fiscal 2025 Third Quarter Financial Results on Monday, August 4, 2025
08:00am, Monday, 14'th Jul 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today
Twist Bioscience Expands Express Delivery Turnaround Time to All Gene Fragments Regardless of Format
08:00am, Monday, 07'th Jul 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today
SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care se
Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference
08:00am, Thursday, 15'th May 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Tuesday, 13'th May 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth
Twist Bioscience and Ginkgo Bioworks Revise Collaboration
08:00am, Thursday, 08'th May 2025
SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care secto
Twist Bioscience: Expansion Efforts Continue To Face Challenges
02:18am, Wednesday, 07'th May 2025
Twist Bioscience reported solid results in Q2, but management's downbeat tone on the earnings call suggest there are challenges ahead. Twist has also spun-out its data storage business, which will hel
Twist Bioscience Corporation (TWST) Q2 2025 Earnings Call Transcript
11:41am, Monday, 05'th May 2025
Twist Bioscience Corporation (NASDAQ:TWST ) Q2 2025 Earnings Conference Call April 5, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust -
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
09:25am, Monday, 05'th May 2025
Twist Bioscience (TWST) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.79 per share a year ago.
Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results
07:15am, Monday, 05'th May 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today
